Qiagen (NYSE:QGEN) Sets New 12-Month Low - What's Next?

Qiagen (NYSE:QGEN - Get Free Report)'s share price reached a new 52-week low during trading on Thursday . The company traded as low as $38.42 and last traded at $38.74, with a volume of 93334 shares traded. The stock had previously closed at $39.15.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. UBS Group reduced their price target on Qiagen from $50.00 to $48.00 and set a "neutral" rating for the company in a research report on Friday, February 7th. Jefferies Financial Group reiterated a "buy" rating and set a $52.50 price target (up from $40.83) on shares of Qiagen in a research report on Tuesday, December 10th. Morgan Stanley restated an "equal weight" rating and issued a $46.67 price objective (down from $48.61) on shares of Qiagen in a research report on Monday, January 6th. Robert W. Baird lowered shares of Qiagen from an "outperform" rating to a "neutral" rating and decreased their target price for the stock from $52.00 to $42.00 in a report on Wednesday, February 19th. Finally, Baird R W cut shares of Qiagen from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 19th. Seven equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $47.71.

Qiagen Trading Down 0.5 %

The stock's 50 day simple moving average is $42.61 and its 200 day simple moving average is $42.85. The firm has a market cap of $8.48 billion, a PE ratio of 106.40, a PEG ratio of 2.39 and a beta of 0.36. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.09 and a current ratio of 3.61.

Remove Ads

Qiagen (NYSE:QGEN - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.01. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. On average, sell-side analysts forecast that Qiagen will post 2.26 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Qiagen

A number of large investors have recently modified their holdings of the company. Brown Brothers Harriman & Co. bought a new position in Qiagen during the fourth quarter valued at approximately $37,000. Geneos Wealth Management Inc. boosted its stake in shares of Qiagen by 41.5% in the 4th quarter. Geneos Wealth Management Inc. now owns 856 shares of the company's stock valued at $38,000 after purchasing an additional 251 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Qiagen by 152.5% during the 4th quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company's stock valued at $39,000 after purchasing an additional 526 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new position in Qiagen in the 3rd quarter worth $53,000. Finally, Smartleaf Asset Management LLC lifted its stake in Qiagen by 148.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company's stock worth $63,000 after purchasing an additional 835 shares during the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.